For U.S. Healthcare Professionals Only
Register for Samples

Toujeo® has widespread coverage

Medicare coverage

As of January 2019 Toujeo is covered for

*Managed Markets Insight and Technology (database). January 2019.


Check the Formulary status for Toujeo (insulin glargine injection) 300 Units/mL in your area

Please check directly with the health plan to confirm coverage.

Powered by Managed Markets Insight & Technology, LLC. Database current as of April 2018.

© 1998-2018 Managed Markets Insight & Technology, LLC. All rights reserved.

*PA= Prior Authorization

**ST= Step Therapy

SOURCE: MMIT Analytics, accessed MMM 2017

SAUS.TJO.18.04.2116

Learn more about efficacy and safety

A1C reduction and safety

Saving with Toujeo

Review savings offers for eligible patients with and without commercial insurance

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis.

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus®.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated.

A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.

As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL SoloStar® and Toujeo Max SoloStar

Toujeo SoloStar and Toujeo Max SoloStar are disposable prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.

Do not withdraw Toujeo from the SoloStar and Max SoloStar disposable prefilled pens with a syringe.

All registered trademarks cited are property of their respective owners.

*

*This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, or TRICARE, or similar federal or state programs, including any state pharmaceutical programs. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of this savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.

  • First 3 fills for $0, next 12 consecutive fills for $10
  • Maximum savings up to $600 per box, up to 3 boxes
*Eligibility Restrictions This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical programs. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of this savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.
Offer Terms for Toujeo Co-Pay Savings Card If your patient is enrolled in a commercial/private insurance plan they will pay a $0 co-pay for the first 3 fills and then pay $10 co-pay for the next 12 consecutive fills for the duration of the program. The Savings Card carries maximum savings of $600 per box. This offer is valid for up to 3 boxes per prescription.
Offer Terms for Insulins Valyou Savings Program: For the duration of the program, eligible patients will pay $149 for each pack of pens. Maximum quantity of ten packs of pens per fill. Offer is valid for one fill per month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. This offer is not valid for the Max SoloStar pen. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.

© 2019 sanofi-aventis U.S. LLC. All rights reserved.

Legal Disclaimer | Privacy Policy | Contact SANOFI

This site is intended for use by U.S. Healthcare Professionals only.

SAUS.TJO.19.01.0569c Last Update: February 2019

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin